ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
ReShape Lifesciences Inc. (Nasdaq: RSLS), a leading weight loss and metabolic health-solutions company, has announced it will release its financial results for the second quarter ended June 30, 2024, along with a corporate update on August 14, 2024, after market close. The company will host a conference call on August 15 at 4:30 pm ET to discuss the results.
Notably, Krishna K. Gupta, a current Director of Vyome Therapeutics, will join the call. Gupta is set to become Chairman of the combined company following the completion of the previously announced merger between ReShape Lifesciences and Vyome Therapeutics.
Investors can access the live webcast through the company's website and participate in the conference call by registering via the provided link. An archived replay will also be available on the company's website after the call.
ReShape Lifesciences Inc. (Nasdaq: RSLS), un'azienda leader nelle soluzioni per la perdita di peso e la salute metabolica, ha annunciato che pubblicherà i suoi risultati finanziari per il secondo trimestre chiuso il 30 giugno 2024, insieme a un aggiornamento aziendale il 14 agosto 2024, dopo la chiusura dei mercati. L'azienda ospiterà una conference call il 15 agosto alle 16:30 ET per discutere i risultati.
È importante notare che Krishna K. Gupta, attuale direttore di Vyome Therapeutics, parteciperà alla chiamata. Gupta è destinato a diventare Presidente dell'azienda combinata dopo il completamento della fusione precedentemente annunciata tra ReShape Lifesciences e Vyome Therapeutics.
Gli investitori possono accedere al webcast in diretta tramite il sito web dell'azienda e partecipare alla conference call registrandosi tramite il link fornito. Sarà inoltre disponibile una registrazione archiviata sul sito web dell'azienda dopo la chiamata.
ReShape Lifesciences Inc. (Nasdaq: RSLS), una empresa líder en soluciones para la pérdida de peso y la salud metabólica, ha anunciado que publicará sus resultados financieros para el segundo trimestre que finalizó el 30 de junio de 2024, junto con una actualización corporativa el 14 de agosto de 2024, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica el 15 de agosto a las 4:30 p. m. ET para discutir los resultados.
Notablemente, Krishna K. Gupta, actual Director de Vyome Therapeutics, se unirá a la llamada. Gupta está destinado a convertirse en Presidente de la empresa combinada tras la finalización de la fusión anunciada previamente entre ReShape Lifesciences y Vyome Therapeutics.
Los inversores pueden acceder a la transmisión en vivo a través del sitio web de la empresa y participar en la conferencia telefónica registrándose a través del enlace proporcionado. También estará disponible una repetición archivada en el sitio web de la empresa después de la llamada.
ReShape Lifesciences Inc. (Nasdaq: RSLS)는 체중 감소 및 대사 건강 솔루션의 선두 기업으로, 2024년 6월 30일 종료된 2분기 재무 결과를 2024년 8월 14일 시장 마감 이후에 발표할 것이라고 발표했습니다. 회사는 8월 15일 오후 4:30 ET에 결과를 논의하기 위해 컨퍼런스 콜을 개최할 예정입니다.
특히, Vyome Therapeutics의 현재 이사인 Krishna K. Gupta가 통화에 참여할 예정입니다. Gupta는 ReShape Lifesciences와 Vyome Therapeutics 간의 previously 발표된 합병이 완료된 후 결합된 회사의 의장이 될 예정입니다.
투자자들은 회사의 웹사이트를 통해 실시간 웹캐스트에 액세스하고 제공된 링크를 통해 등록하여 컨퍼런스 콜에 참여할 수 있습니다. 통화 후 회사 웹사이트에서 아카이브된 재생도 제공될 것입니다.
ReShape Lifesciences Inc. (Nasdaq: RSLS), une entreprise leader dans les solutions de perte de poids et de santé métabolique, a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre clos le 30 juin 2024, ainsi qu'une mise à jour de l'entreprise le 14 août 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique le 15 août à 16h30 ET pour discuter des résultats.
Il est à noter que Krishna K. Gupta, directeur actuel de Vyome Therapeutics, se joindra à l'appel. Gupta devrait devenir président de l'entreprise combinée après l'achèvement de la fusion précédemment annoncée entre ReShape Lifesciences et Vyome Therapeutics.
Les investisseurs peuvent accéder au webcast en direct via le site Web de l'entreprise et participer à la conférence téléphonique en s'inscrivant via le lien fourni. Un replay archivé sera également disponible sur le site Web de l'entreprise après l'appel.
ReShape Lifesciences Inc. (Nasdaq: RSLS), ein führendes Unternehmen im Bereich Gewichtsreduktion und metabolische Gesundheitslösungen, hat angekündigt, seine finanziellen Ergebnisse für das zweite Quartal zum 30. Juni 2024 zusammen mit einem Unternehmensupdate am 14. August 2024 nach Börsenschluss zu veröffentlichen. Das Unternehmen wird am 15. August um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
Besonders hervorzuheben ist, dass Krishna K. Gupta, derzeitiger Direktor von Vyome Therapeutics, an der Telefonkonferenz teilnehmen wird. Gupta wird voraussichtlich Vorsitzender des fusionierten Unternehmens werden, nachdem die zuvor angekündigte Fusion zwischen ReShape Lifesciences und Vyome Therapeutics abgeschlossen ist.
Investoren können über die Unternehmenswebsite auf das Live-Webcast zugreifen und sich über den bereitgestellten Link für die Telefonkonferenz registrieren. Eine archivierte Wiederholung wird ebenfalls nach dem Anruf auf der Unternehmenswebsite verfügbar sein.
- Upcoming release of Q2 2024 financial results
- Planned corporate update alongside financial results
- Progress in previously announced merger with Vyome Therapeutics
- None.
Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2024, including a corporate update on Wednesday, August 14, 2024, after market.
Management will host a conference call on August 15 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.
To participate in the conference call please register with the following Registration Link, and dial-in details will be provided. Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.
An archived replay will also be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
CONTACTS:
ReShape Lifesciences Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com
FAQ
When will ReShape Lifesciences (RSLS) report its Q2 2024 financial results?
When is the ReShape Lifesciences (RSLS) Q2 2024 earnings conference call scheduled?
Who will join ReShape Lifesciences (RSLS) management on the Q2 2024 earnings call?
How can investors access ReShape Lifesciences' (RSLS) Q2 2024 earnings call?
